GLP-1 & compounded medication availability in Virginia (2026)

Virginia writes its expectations into the state code more plainly than most states: an out-of-state pharmacy that ships prescriptions to Virginia patients must be registered with the state and must name a pharmacist-in-charge, and its health-professions agency holds compounding to the national USP standards through published guidance. Nothing in that framework is specific to GLP-1s or peptides, and we checked the code sections themselves rather than assuming. Here is the full ten-line picture for Virginia addresses, including the two lines we do not ship anywhere.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Virginia: all ten lines

Availability of all ten OrderlyMeds product lines in Virginia, with typical delivery times and notes
Product lineAvailable in Virginia?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Filled on patient-specific prescriptions by partner pharmacies registered with Virginia as nonresident pharmacies.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same registered-pharmacy flow; flat national price at every dose.
NAD+ Yes 8–10 business days Ships from licensed partner pharmacies registered for Virginia.
Sermorelin Yes 8–10 business days Longevity family; standard ordering flow applies.
Glutathione No N/A Not in the OrderlyMeds formulary today.
BPC-157 Yes 8–10 business days Compounded injectable. Its federal record is below.
TB-500 Yes 8–10 business days Compounded injectable; read its own section first.
KPV No N/A Not carried in any state; our peptide lines are injectables only.
Epitalon Yes 8–10 business days Compounded injectable; federal picture below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record is its own, below.

A “No” row is information, not an apology. Virginia facts on this page were last reviewed on November 16, 2026.

Research peptides in Virginia: BPC-157, TB-500, KPV, Epitalon & MOTS-c

The Virginia answer on research peptides matches our national catalog: BPC-157, TB-500, Epitalon and MOTS-c ship as compounded injectables on patient-specific prescriptions, and KPV does not ship at all, because we compound these lines as injectables only. Virginia’s registration and USP requirements attach to the pharmacies doing that compounding rather than to the substances, so the sections below carry what actually distinguishes these five lines: each one’s own federal record, stated in full whether the line is available to you or not.

BPC-157 in Virginia

BPC-157 is dispensed to Virginia addresses as a compounded injectable on a patient-specific prescription. Both federal facts below apply without modification.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Virginia

Virginia orders for TB-500 are compounded injectables filled on patient-specific prescriptions. Its federal record is set out below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Virginia

KPV does not ship to Virginia or anywhere else from our catalog, because these peptide lines are compounded as injectables only and KPV is not carried in that form.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Virginia

Epitalon reaches Virginia addresses as a compounded injectable under a patient-specific prescription. The federal facts below apply as written.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Virginia

MOTS-c ships to Virginia as a compounded injectable on a patient-specific prescription. Its federal record stands apart from the four lines above and is stated below on its own terms.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Virginia’s pharmacy regulators say about compounded medications

Virginia’s framework has two load-bearing pieces for a telehealth patient: a registration requirement written directly into the state code for any out-of-state pharmacy shipping into the Commonwealth, and published agency guidance holding compounding practice to USP chapters. Both are cited below from the state’s own sources. Neither singles out any medication on this page.

Any pharmacy located outside Virginia that ships, mails or delivers prescription drugs to Virginia patients is a nonresident pharmacy under Va. Code § 54.1-3434.1, must be registered with the Board of Pharmacy, and must designate a pharmacist-in-charge; § 54.1-3434.4 makes shipping without registration unlawful. Source: Code of Virginia, Title 54.1, Chapter 34, Article 2.1.

Virginia’s Board of Pharmacy holds pharmacies to USP compounding standards through its published guidance on compliance with USP chapters (Guidance Document 110-36, effective June 2024); no GLP-1-specific or peptide-specific prohibition has been published by the board. Source: Virginia Department of Health Professions — Board of Pharmacy.

Virginia requires a bona fide practitioner–patient relationship for prescribing, which may be established through a real-time telemedicine encounter meeting the standard of care; an online questionnaire alone does not establish it. Source: Center for Connected Health Policy (CCHP) Policy Finder.

The questionnaire point in that last citation is worth a sentence: Virginia’s telemedicine standard rules out form-and-ship models, and OrderlyMeds’ flow, a real evaluation by a Virginia-licensed provider before any prescription exists, is built for exactly that standard. Fulfillment then comes from partner pharmacies registered with the state, at the same national price as everywhere else. One honest data note: Virginia’s traffic ranks high in our analytics partly because of Ashburn’s datacenters, but the availability facts on this page are researched, not traffic-driven.

Virginia availability FAQs

Is compounded semaglutide available in Virginia?

Yes. OrderlyMeds ships compounded semaglutide to Virginia addresses on patient-specific prescriptions, through partner pharmacies registered with Virginia as nonresident pharmacies. New customers start at $74/month for the first two months.

Can I get a prescription in Virginia from just an online form?

No, and that is Virginia’s standard, not ours alone. The state requires a bona fide practitioner–patient relationship, which a real-time telehealth evaluation establishes and a standalone questionnaire does not. Every OrderlyMeds prescription follows an individual evaluation by a Virginia-licensed provider.

Can I get BPC-157 or other research peptides shipped to Virginia?

BPC-157, TB-500, Epitalon and MOTS-c ship to Virginia as compounded injectables on patient-specific prescriptions; KPV does not, because we compound these lines as injectables only. Each line’s own federal record is stated in its section above and applies wherever you buy.

How long does delivery to Virginia take?

Our published window is 8–10 business days from signup.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone